MARKET

CBAY

CBAY

CymaBay
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.800
-0.090
-2.31%
Closed 17:20 09/24 EDT
OPEN
3.850
PREV CLOSE
3.890
HIGH
3.900
LOW
3.790
VOLUME
170.38K
TURNOVER
--
52 WEEK HIGH
9.06
52 WEEK LOW
3.390
MARKET CAP
262.19M
P/E (TTM)
-3.8559
1D
5D
1M
3M
1Y
5Y
A Look At The Fair Value Of CymaBay Therapeutics, Inc. (NASDAQ:CBAY)
Today we will run through one way of estimating the intrinsic value of CymaBay Therapeutics, Inc. ( NASDAQ:CBAY ) by...
Simply Wall St. · 09/02 11:38
CymaBay Therapeutics to Present at Upcoming Investor Conferences
NEWARK, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that manageme...
GlobeNewswire · 08/30 12:00
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
B. Riley Lowers Cymabay Therapeutics' PT to $10 from $13, Keeps Buy Rating
MT Newswires · 08/18 09:41
CymaBay Therapeutics Q2 EPS $(0.34) Misses $(0.27) Estimate
CymaBay Therapeutics (NASDAQ:CBAY) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.27) by 25.93 percent. This is a 112.5 percent decrease over losses of $(0.16) per share
Benzinga · 08/12 20:47
CymaBay Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update
Secured up to $100 million of additional development funding through a non-dilutive financing transaction with Abingworth
GlobeNewswire · 08/12 20:06
-- Earnings Flash (CBAY) CYMABAY THERAPEUTICS Reports Q2 Loss $-0.34
MT Newswires · 08/12 16:16
Earnings Reaction History: CymaBay Therapeutics Inc, 66.7% Follow-Through Indicator, 18.4% Sensitive
MT Newswires · 08/12 12:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CBAY. Analyze the recent business situations of CymaBay through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CBAY stock price target is 10.80 with a high estimate of 14.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 186
Institutional Holdings: 64.72M
% Owned: 93.80%
Shares Outstanding: 69.00M
TypeInstitutionsShares
Increased
26
1.59M
New
11
785.79K
Decreased
41
5.18M
Sold Out
28
907.59K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Robert Wills
President/Chief Executive Officer/Director
Sujal Shah
Senior Vice President/Chief Scientific Officer
Charles McWherter
Chief Compliance Officer/General Counsel/Secretary
Paul Quinlan
Vice President - Finance
Daniel Menold
Other
Klara Dickinson
Other
Dennis Kim
Other
Lewis Stuart
Director
Janet Dorling
Independent Director
Caroline Loewy
Independent Director
Kurt Von Emster
Independent Director
Thomas Wiggans
No Data
About CBAY
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. Its pipeline includes Seladelpar, MBX-2982 and CB-001. The Company’s lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The PPARd receptor is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells. Seladelpar focuses on treating certain diseases of the liver and a variety of disorders of lipid metabolism.

Webull offers kinds of CymaBay Therapeutics Inc stock information, including NASDAQ:CBAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBAY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CBAY stock methods without spending real money on the virtual paper trading platform.